The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics
Standard
The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics. / Schons, Maximilian; Pilgram, Lisa; Reese, Jens-Peter; Stecher, Melanie; Anton, Gabriele; Appel, Katharina S; Bahmer, Thomas; Bartschke, Alexander; Bellinghausen, Carla; Bernemann, Inga; Brechtel, Markus; Brinkmann, Folke; Brünn, Clara; Dhillon, Christine; Fiessler, Cornelia; Geisler, Ramsia; Hamelmann, Eckard; Hansch, Stefan; Hanses, Frank; Hanß, Sabine; Herold, Susanne; Heyder, Ralf; Hofmann, Anna-Lena; Hopff, Sina Marie; Horn, Anna; Jakob, Carolin; Jiru-Hillmann, Steffi; Keil, Thomas; Khodamoradi, Yascha; Kohls, Mirjam; Kraus, Monika; Krefting, Dagmar; Kunze, Sonja; Kurth, Florian; Lieb, Wolfgang; Lippert, Lena Johanna; Lorbeer, Roberto; Lorenz-Depiereux, Bettina; Maetzler, Corina; Miljukov, Olga; Nauck, Matthias; Pape, Daniel; Püntmann, Valentina; Reinke, Lennart; Römmele, Christoph; Rudolph, Stefanie; Sass, Julian; Schäfer, Christian; Schaller, Jens; Schattschneider, Mario; Scheer, Christian; Scherer, Margarete; Schmidt, Sein; Schmidt, Julia; Seibel, Kristina; Stahl, Dana; Steinbeis, Fridolin; Störk, Stefan; Tauchert, Maike; Tebbe, Johannes Josef; Thibeault, Charlotte; Toepfner, Nicole; Ungethüm, Kathrin; Vadasz, Istvan; Valentin, Heike; Wiedmann, Silke; Zoller, Thomas; Nagel, Eike; Krawczak, Michael; von Kalle, Christof; Illig, Thomas; Schreiber, Stefan; Witzenrath, Martin; Heuschmann, Peter; Vehreschild, Jörg Janne; NAPKON Study Group.
in: EUR J EPIDEMIOL, Jahrgang 37, Nr. 8, 08.2022, S. 849-870.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics
AU - Schons, Maximilian
AU - Pilgram, Lisa
AU - Reese, Jens-Peter
AU - Stecher, Melanie
AU - Anton, Gabriele
AU - Appel, Katharina S
AU - Bahmer, Thomas
AU - Bartschke, Alexander
AU - Bellinghausen, Carla
AU - Bernemann, Inga
AU - Brechtel, Markus
AU - Brinkmann, Folke
AU - Brünn, Clara
AU - Dhillon, Christine
AU - Fiessler, Cornelia
AU - Geisler, Ramsia
AU - Hamelmann, Eckard
AU - Hansch, Stefan
AU - Hanses, Frank
AU - Hanß, Sabine
AU - Herold, Susanne
AU - Heyder, Ralf
AU - Hofmann, Anna-Lena
AU - Hopff, Sina Marie
AU - Horn, Anna
AU - Jakob, Carolin
AU - Jiru-Hillmann, Steffi
AU - Keil, Thomas
AU - Khodamoradi, Yascha
AU - Kohls, Mirjam
AU - Kraus, Monika
AU - Krefting, Dagmar
AU - Kunze, Sonja
AU - Kurth, Florian
AU - Lieb, Wolfgang
AU - Lippert, Lena Johanna
AU - Lorbeer, Roberto
AU - Lorenz-Depiereux, Bettina
AU - Maetzler, Corina
AU - Miljukov, Olga
AU - Nauck, Matthias
AU - Pape, Daniel
AU - Püntmann, Valentina
AU - Reinke, Lennart
AU - Römmele, Christoph
AU - Rudolph, Stefanie
AU - Sass, Julian
AU - Schäfer, Christian
AU - Schaller, Jens
AU - Schattschneider, Mario
AU - Scheer, Christian
AU - Scherer, Margarete
AU - Schmidt, Sein
AU - Schmidt, Julia
AU - Seibel, Kristina
AU - Stahl, Dana
AU - Steinbeis, Fridolin
AU - Störk, Stefan
AU - Tauchert, Maike
AU - Tebbe, Johannes Josef
AU - Thibeault, Charlotte
AU - Toepfner, Nicole
AU - Ungethüm, Kathrin
AU - Vadasz, Istvan
AU - Valentin, Heike
AU - Wiedmann, Silke
AU - Zoller, Thomas
AU - Nagel, Eike
AU - Krawczak, Michael
AU - von Kalle, Christof
AU - Illig, Thomas
AU - Schreiber, Stefan
AU - Witzenrath, Martin
AU - Heuschmann, Peter
AU - Vehreschild, Jörg Janne
AU - NAPKON Study Group
AU - Addo, Marylyn Martina
N1 - © 2022. The Author(s).
PY - 2022/8
Y1 - 2022/8
N2 - The German government initiated the Network University Medicine (NUM) in early 2020 to improve national research activities on the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic. To this end, 36 German Academic Medical Centers started to collaborate on 13 projects, with the largest being the National Pandemic Cohort Network (NAPKON). The NAPKON's goal is creating the most comprehensive Coronavirus Disease 2019 (COVID-19) cohort in Germany. Within NAPKON, adult and pediatric patients are observed in three complementary cohort platforms (Cross-Sectoral, High-Resolution and Population-Based) from the initial infection until up to three years of follow-up. Study procedures comprise comprehensive clinical and imaging diagnostics, quality-of-life assessment, patient-reported outcomes and biosampling. The three cohort platforms build on four infrastructure core units (Interaction, Biosampling, Epidemiology, and Integration) and collaborations with NUM projects. Key components of the data capture, regulatory, and data privacy are based on the German Centre for Cardiovascular Research. By April 01, 2022, 34 university and 40 non-university hospitals have enrolled 5298 patients with local data quality reviews performed on 4727 (89%). 47% were female, the median age was 52 (IQR 36-62-) and 50 pediatric cases were included. 44% of patients were hospitalized, 15% admitted to an intensive care unit, and 12% of patients deceased while enrolled. 8845 visits with biosampling in 4349 patients were conducted by April 03, 2022. In this overview article, we summarize NAPKON's design, relevant milestones including first study population characteristics, and outline the potential of NAPKON for German and international research activities.Trial registration https://clinicaltrials.gov/ct2/show/NCT04768998 . https://clinicaltrials.gov/ct2/show/NCT04747366 . https://clinicaltrials.gov/ct2/show/NCT04679584.
AB - The German government initiated the Network University Medicine (NUM) in early 2020 to improve national research activities on the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic. To this end, 36 German Academic Medical Centers started to collaborate on 13 projects, with the largest being the National Pandemic Cohort Network (NAPKON). The NAPKON's goal is creating the most comprehensive Coronavirus Disease 2019 (COVID-19) cohort in Germany. Within NAPKON, adult and pediatric patients are observed in three complementary cohort platforms (Cross-Sectoral, High-Resolution and Population-Based) from the initial infection until up to three years of follow-up. Study procedures comprise comprehensive clinical and imaging diagnostics, quality-of-life assessment, patient-reported outcomes and biosampling. The three cohort platforms build on four infrastructure core units (Interaction, Biosampling, Epidemiology, and Integration) and collaborations with NUM projects. Key components of the data capture, regulatory, and data privacy are based on the German Centre for Cardiovascular Research. By April 01, 2022, 34 university and 40 non-university hospitals have enrolled 5298 patients with local data quality reviews performed on 4727 (89%). 47% were female, the median age was 52 (IQR 36-62-) and 50 pediatric cases were included. 44% of patients were hospitalized, 15% admitted to an intensive care unit, and 12% of patients deceased while enrolled. 8845 visits with biosampling in 4349 patients were conducted by April 03, 2022. In this overview article, we summarize NAPKON's design, relevant milestones including first study population characteristics, and outline the potential of NAPKON for German and international research activities.Trial registration https://clinicaltrials.gov/ct2/show/NCT04768998 . https://clinicaltrials.gov/ct2/show/NCT04747366 . https://clinicaltrials.gov/ct2/show/NCT04679584.
KW - Adult
KW - COVID-19/epidemiology
KW - Child
KW - Clinical Trials as Topic
KW - Female
KW - Humans
KW - Intensive Care Units
KW - Male
KW - Middle Aged
KW - Pandemics
KW - Research Design
KW - SARS-CoV-2
U2 - 10.1007/s10654-022-00896-z
DO - 10.1007/s10654-022-00896-z
M3 - SCORING: Review article
C2 - 35904671
VL - 37
SP - 849
EP - 870
JO - EUR J EPIDEMIOL
JF - EUR J EPIDEMIOL
SN - 0393-2990
IS - 8
ER -